XML 22 R8.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2024
Sep. 30, 2023
Cash Provided by (Used in) Operating Activities      
Net earnings $ 2,293 $ 8,225 $ 6,070
Adjustments to reconcile net earnings to operating cash flows:      
Depreciation and amortization   213 194
Deferred income tax provision (benefit) [1]   459 (241)
Unrecognized tax benefit [1]   80 830
(Income) losses from investments in equity securities (116) (530) (105)
Gain on the sale of IQOS System commercialization rights 0 (2,700) 0
Dividends from ABI   139 163
Asset impairment 0 354 0
Cash effects of changes      
Receivables [2]   (14) 19
Inventories [2]   114 26
Accounts payable [2]   (68) (47)
Income taxes [2]   396 (210)
Accrued liabilities and other current assets [2]   (919) (210)
Accrued settlement charges [2]   (445) (537)
Pension plan contributions   (13) (14)
Pension and postretirement, net   (76) (97)
Other, net   198 219
Net cash provided by (used in) operating activities   5,413 6,060
Cash Provided by (Used in) Investing Activities      
Capital expenditures   (95) (143)
Proceeds from the ABI Transaction [3]   2,353 0
Proceeds from the sale of IQOS System commercialization rights   0 1,700
Acquisition of NJOY, net of cash acquired   0 (2,751)
Other, net   (20) (23)
Net cash provided by (used in) investing activities   2,238 (1,217)
Cash Provided by (Used in) Financing Activities      
Proceeds from short-term borrowings   0 2,000
Repayment of short-term borrowings   0 (2,000)
Long-term debt repaid   (1,121) (1,566)
Repurchase of common stock   (3,090) (732)
Dividends paid on common stock   (5,108) (5,040)
Other, net   (125) (15)
Net cash provided by (used in) financing activities   (9,444) (7,353)
Cash, cash equivalents and restricted cash:      
Increase (decrease)   (1,793) (2,510)
Balance at beginning of period   3,721 4,091
Balance at end of period 1,928 1,928 $ 1,581
Cash and cash equivalents 1,897 1,897  
Restricted cash included in other current assets [4] 8 8  
Restricted cash included in other assets [4] $ 23 $ 23  
[1] 2023 relates to unrecognized tax benefit from the ordinary loss for cash tax purposes with respect to a portion of our tax basis associated with our former investment in JUUL, partially offset by our estimated corporate alternative minimum tax credit carryforward. 2023 amounts have been reclassified to conform to the current year presentation.
[2] 2023 amounts are net of the effects from the NJOY Transaction. See Note 2. Acquisition of NJOY.
[3] See Note 6. Investments in Equity Securities.
[4] Restricted cash consisted of cash deposits collateralizing appeal bonds posted by PM USA to obtain stays of judgments pending appeals. See Note 14. Contingencies.